GW Pharmaceuticals (GWPH) Stock Price, News & Analysis

Company Overview

GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics from its proprietary cannabinoid product platform in various disease areas. Its lead product is Epidiolex, an oral medicine for the treatment of seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex. The company also develops and markets Sativex for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of schizophrenia, autism spectrum disorder, neuropsychiatric symptom, and neonatal hypoxic ischemic encephalopathy. It primarily operates in Europe, the United Kingdom, the United States, and internationally. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.

Key Stats

• Today's Range: $218.96 to $218.96
• 50-Day Range: $216.90 to $219.28
• 52-Week Range: $87.07 to $219.57
• Volume: N/A
• Average Volume: 899,771 shs
• Market Capitalization: $6.86 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GWPH Stock Analysis - Frequently Asked Questions

How were GW Pharmaceuticals' earnings last quarter?

GW Pharmaceuticals plc (NASDAQ:GWPH) released its earnings results on Tuesday, November, 3rd. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.63) by $0.27. The business's quarterly revenue was up 50.7% compared to the same quarter last year.

What other stocks do shareholders of GW Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GW Pharmaceuticals investors own include NVIDIA (NVDA), Canopy Growth (CGC), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/03/2020
• Today: 2/04/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:GWPH
• CUSIP: N/A
• CIK: 1351288
• Web: www.gwpharm.com
• Phone: 44-12-2326-6800
• Fax: N/A
• Employees: 1,161
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-9,020,000.00
• Net Margins: -11.05%
• Pretax Margin: N/A
• Return on Equity: -7.46%
• Return on Assets: -6.13%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.13
• Quick Ratio: 4.31

Sales & Book Value

• Annual Sales: $311.33 million
• Price / Sales: 22.05
• Cash Flow: $0.01 per share
• Price / Cash Flow: 18,588.22
• Book Value: $23.48 per share
• Price / Book: 9.33

Miscellaneous

• Outstanding Shares: 31,349,000
• Free Float: N/A
• Market Cap: $6.86 billion
• Optionable: Optionable
• Beta: 2.15